戈利木单抗——对抗炎症性关节炎的新武器。

Golimumab - a new tool in the armoury against inflammatory arthritis.

机构信息

Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, UK.

出版信息

Ann Med. 2011 Mar;43(2):133-41. doi: 10.3109/07853890.2010.549148. Epub 2011 Jan 18.

DOI:10.3109/07853890.2010.549148

Abstract

The development of biological drugs blocking tumour necrosis factor-alpha (TNF-α) has had a dramatic impact on the treatment of inflammatory arthritis in recent years. Golimumab is a fully human monoclonal antibody which inhibits TNF-α. It is licensed for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. In this review we evaluate the results of phase III studies using golimumab and explore the place of golimumab in the treatment of these diseases.

摘要

近年来，阻断肿瘤坏死因子-α（TNF-α）的生物药物的发展对炎症性关节炎的治疗产生了巨大影响。戈利木单抗是一种完全人源化的单克隆抗体，可抑制 TNF-α。它被批准用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎。在这篇综述中，我们评估了使用戈利木单抗的 III 期研究结果，并探讨了戈利木单抗在这些疾病治疗中的地位。